Home » Business News » 2011 » May » May 6, 2011

Annual General Meeting of Active Biotech AB

May 6, 2011 - LUND, SWEDEN

The Annual General Meeting of Active Biotechwas held on May 5, 2011.

In accordance with the Board of Directors' proposal, it was resolved thatnodividend would be paid.

In accordance with the Election Committee's proposal, the Board membersMatsArnhög, Klas Kärre, Magnhild Sandberg and Peter Sjöstrandwere re-elected. PeterHofvenstam, Mef Nilbert and Peter Thelin were elected as Boardmembers. TheMeeting also resolved to re-elect Mats Arnhög as Chairman of theBoard.

Furthermore, in accordance with the Election Committee's proposal, theMeetingresolved that the Election Committee shall be composed of representativesforthe three largest owners, as per end of September, 2011, as well as theChairmanof the Board.

The Meeting approved the Board's proposal concerning guidelines forremunerationto the President and other senior executives. The guidelines essentiallyconformto the principles applied to date.

In accordance with the Board's proposal, the Meeting resolved to authorizetheBoard, for a period that does not extend past the date of the next AnnualGeneral Meeting, to resolve on the issue of not more than six million newsharesand/or convertibles with the corresponding dilution effect, with or withoutpre-emptive rights for the company's shareholders.

Finally, pursuant to new provisions in the Swedish Companies Act, themeetingapproved an amendment of the Articles of Association (Section 7), asfollows:Notice of general meetings shall be made through announcement inPost- ochInrikes Tidningar and on the company's website. It shall be announced inSvenskaDagbladet that a notice of a general meeting has been issued.

Lund, May 6, 2011

Active Biotech AB (publ)

Tomas Leanderson

President and CEO

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology companywithfocus on autoimmune/inflammatory diseases and cancer. Projects in pivotalphaseare laquinimod, an orally administered small molecule withuniqueimmunomodulatory properties for the treatment of multiple sclerosis,TASQ forProstate cancer and ANYARA for use in cancer targeted therapy,primarily ofrenal cell cancer. In addition, laquinimod is in Phase IIdevelopment forCrohn's and Lupus. Further projects in clinical development comprisethe twoorally administered compounds, 57- 57 for SLE and Systemic Sclerosis aswell asRhuDex™ for RA. Please visit for moreinformation.

Active Biotech is required under the Financial Instruments Trading Act tomakethe information in this press release public. The information was submittedforpublication at 08:30 a.m. CET on May 6, 2011.

Annual General Meeting of Active Biotech AB:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright andother applicable laws; and

(ii) they are solely responsible for the content, accuracy andoriginality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE


Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


Comment on this story